Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.
Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.
复制标题
DOI：
10.3390/ijerph182111045
复制
发表时间：
2021-10-21
影响因子：
--
通讯作者：
Pawloski PA
中科院分区：
文献类型：
--
作者：
Davis TC;Arnold CL;Mills G;Lesser GJ;Brown WM;Schulz R;Weaver KE;Pawloski PA
本试验研究的目的是评估慢性粒细胞白血病（CML）患者对口服抗癌药（OAC）的依从性、信念和障碍，采用社区癌症诊所的简短自我报告措施。患者完成了结构化访谈，包括健康素养评估，简要用药问卷，两个单项自我报告依从性问题，和药物依从性原因量表。在86名参与者中，88.4%为白色; 55.8%为男性;平均年龄为58.7岁; 22.1%的健康素养有限。18.6%的受试者报告了不依从（上周至少漏服一剂），并且与不太优秀的服用CML药物的感知能力（16.3%）相关（p < 0.003）。黑人参与者报告服用CML药物的困难比白色参与者更大（28.6% vs. 8.3%，p = 0.053）。在所有参与者中，43.0%的人报告他们的CML药物无效，24.4%的人报告服用CML药物有些困难。最常见的漏服原因是漏服（24.4%）和副作用（18.6%）。大多数患者认为他们服用CML药物的能力是好到优秀的，但近五分之一的患者报告在过去一周内错过了至少一剂药物。简单、无成本的自我报告评估来筛查CML患者的OAC依从性、障碍和信念，可以促进忙碌癌症诊所的咨询。
The purpose of this pilot study was to assess Chronic Myeloid Leukemia (CML) patients’ adherence to, beliefs about, and barriers to oral anticancer agents (OAC) using brief self-report measures in community-based cancer clinics. Patients completed a structured interview including a health literacy assessment, a Brief Medication Questionnaire, two single-item self-report adherence questions, and the Medications Adherence Reasons Scale. Of the 86 participants, 88.4% were white; 55.8% male; mean age, 58.7 years; and 22.1% had limited health literacy. Nonadherence (missing at least one dose in the last week) was reported by 18.6% of participants and associated (p < 0.003) with less-than-excellent perceived ability to take CML medications (16.3%). Black participants reported more difficulty taking CML medications than white participants (28.6% vs. 8.3%, p = 0.053). Among all participants, 43.0% reported their CML medicine was ineffective and 24.4% that taking CML pills was somewhat to very hard. The most common reasons for missing a dose were simply missed it (24.4%) and side effects (18.6%). Most patients perceived their ability to take CML medication was good to excellent, yet nearly one in five reported missing at least one dose in the last week. Brief, no-cost self-report assessments to screen CML patients’ OAC adherence, barriers, and beliefs could facilitate counseling in busy community cancer clinics.
登录
查看更多内容
影响因子：
5.7
作者：
Davis, Terry C.;Federman, Alex D.;Wolf, Michael S.
通讯作者：
Wolf, Michael S.
影响因子：
2.7
作者：
Efficace, Fabio;Rosti, Gianantonio;Baccarani, Michele
通讯作者：
Baccarani, Michele
影响因子：
1.3
作者：
Anderson, Kristin R.;Chambers, Carole R.;Sheikh, Naureen
通讯作者：
Sheikh, Naureen
影响因子：
3.5
作者：
Cameron KA;Ross EL;Clayman ML;Bergeron AR;Federman AD;Bailey SC;Davis TC;Wolf MS
通讯作者：
Wolf MS
遵守BCR-ABL抑制剂：CML治疗问题。
DOI：
10.1016/j.clml.2012.04.002
发表时间：
2012-08
期刊：
Clinical lymphoma, myeloma & leukemia
影响因子：
--
作者：
Jabbour E;Saglio G;Radich J;Kantarjian H
通讯作者：
Kantarjian H